Mucosal vaccination against tuberculosis using Ag85A-loaded immunostimulating complexes

Tuberculosis (TB) is one of the major devastating diseases in the world, mainly caused by Mycobacterium tuberculosis. Furthermore, multi-drug resistant TB and extremely drug resistant TB are becoming big problems globally. Bacillus Calmette-Guerin (BCG) is the only available vaccine which provides protection against TB. The BCG vaccine is effective in children but not recommended in adults and elderly patients due to an associated low risk of infection with Mycobacterium tuberculosis and variable effectiveness of the vaccine. The main aim of this research study is to develop such a vaccine which will provide a better and safer profile in children and adults, as well as in elderly patients. In this present study, we prepared pulmonary tubercular vaccine by using an Antigen 85 complex (Ag85)-loaded nanocarrier such as the immunostimulating complex (ISCOM). Immunological outcomes clearly indicated significant improvement in humoral as well as cellular immune responses after pulmonary immunization with ISCOMs containing Quil A in mice.

[1]  Tarun Garg,et al.  Current nanotechnological approaches for an effective delivery of bio-active drug molecules in the treatment of acne , 2016, Artificial cells, nanomedicine, and biotechnology.

[2]  Vedant Modgill,et al.  Permeability study of ciprofloxacin from ultra-thin nanofibrous film through various mucosal membranes , 2016, Artificial cells, nanomedicine, and biotechnology.

[3]  T. Garg,et al.  Preparation and characterization of spray-dried inhalable powders containing nanoaggregates for pulmonary delivery of anti-tubercular drugs , 2016, Artificial cells, nanomedicine, and biotechnology.

[4]  T. Garg,et al.  Nanofibers as novel drug carrier – An overview , 2016, Artificial cells, nanomedicine, and biotechnology.

[5]  Gaurav Chauhan,et al.  Development and characterization of niosomal gel for topical delivery of benzoyl peroxide , 2015, Drug delivery.

[6]  T. Garg,et al.  Transmucosal delivery of Docetaxel by mucoadhesive polymeric nanofibers , 2015, Artificial cells, nanomedicine, and biotechnology.

[7]  T. Garg,et al.  Development and characterization of guar gum nanoparticles for oral immunization against tuberculosis , 2015, Drug delivery.

[8]  T. Garg,et al.  Development and characterization of nanocarriers for topical treatment of psoriasis by using combination therapy , 2014, Artificial cells, nanomedicine, and biotechnology.

[9]  T. Garg,et al.  Recent approaches of lipid-based delivery system for lymphatic targeting via oral route , 2014, Journal of drug targeting.

[10]  Amit K. Goyal,et al.  Biomaterial-based scaffolds – current status and future directions , 2014, Expert opinion on drug delivery.

[11]  Tarun Goyal.  Liposomes: Targeted and Controlled Delivery System , 2014 .

[12]  Gagandeep,et al.  Development and characterization of nano-fiber patch for the treatment of glaucoma. , 2014, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[13]  Magdalini Moutaftsi,et al.  Protection against Tuberculosis with Homologous or Heterologous Protein/Vector Vaccine Approaches Is Not Dependent on CD8+ T Cells , 2013, The Journal of Immunology.

[14]  I. Orme.  Vaccine Development for Tuberculosis: Current Progress , 2013, Drugs.

[15]  T. Garg,et al.  Nanotechnological Approaches for Genetic Immunization , 2013, DNA and RNA Nanobiotechnologies in Medicine: Diagnosis and Treatment of Diseases.

[16]  M. Beyens,et al.  Complications of BCG vaccine SSI® recent story and risk management plan: the French experience , 2013, Pharmacoepidemiology and drug safety.

[17]  F. Santoyo-González,et al.  Functionalization of immunostimulating complexes (ISCOMs) with lipid vinyl sulfones and their application in immunological techniques and therapy , 2012, International journal of nanomedicine.

[18]  T. Garg,et al.  Development, Optimization & Evaluation of Porous Chitosan Scaffold Formulation of Gliclazide for the Treatment of Type-2 Diabetes Mellitus , 2012 .

[19]  Tarun Goyal.  Iontophoresis: Drug Delivery System by Applying an Electrical Potential Across the Skin , 2012 .

[20]  M. Horton,et al.  Pulmonary Vaccination as a Novel Treatment for Lung Fibrosis , 2012, PloS one.

[21]  U. Bickel,et al.  Liposome-Encapsulated Polyethylenimine/Oligonucleotide Polyplexes Prepared by Reverse-Phase Evaporation Technique , 2012, AAPS PharmSciTech.

[22]  H. Matsuda,et al.  Adjuvant and Haemolytic Activities of 47 Saponins Derived from Medicinal and Food Plants , 2000, Biological chemistry.

[23]  K. Granfors.  Measurement of immunoglobulin M (IgM), IgG, and IgA antibodies against Yersinia enterocolitica by enzyme-linked immunosorbent assay: persistence of serum antibodies during disease , 1979, Journal of clinical microbiology.

[24]  T. Garg,et al.  Ancient and advanced approaches for the treatment of an inflammatory autoimmune disease-psoriasis. , 2014, Critical reviews in therapeutic drug carrier systems.

[25]  T. Garg,et al.  Current nanotechnological strategies for effective delivery of bioactive drug molecules in the treatment of tuberculosis. , 2014, Critical reviews in therapeutic drug carrier systems.

[26]  Tarun Garg,et al.  Scaffold: a novel carrier for cell and drug delivery. , 2012, Critical reviews in therapeutic drug carrier systems.

[27]  Jianping Xie,et al.  Novel insights into Mycobacterium antigen Ag85 biology and implications in countermeasures for M. tuberculosis. , 2012, Critical reviews in eukaryotic gene expression.

[28]  P. Sylvester,et al.  Optimization of the tetrazolium dye (MTT) colorimetric assay for cellular growth and viability. , 2011, Methods in molecular biology.

[29]  Y. Perrie,et al.  PLGA microspheres for the delivery of a novel subunit TB vaccine. , 2008, Journal of drug targeting.